Publications

Assessing the efficiency of catch-up campaigns for the introduction of pneumococcal conjugate vaccine: a modelling study based on data from PCV10 introduction in Kilifi, Kenya.

FLASCHE, S; OJAL, J; LE POLAIN DE WAROUX, O; OTIENDE, M; O'Brien, KL; Kiti, M; Nokes, DJ; EDMUNDS, WJ; SCOTT, JA G;

2017

BMC medicine, (2017).15 1 10.1186/s12916-017-0882-9.

TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development.

Kaufmann, SH E; DOCKRELL, HM; Drager, N; Ho, MM; McShane, H; Neyrolles, O; Ottenhoff, TH M; Patel, B; Roordink, D; Spertini, F; Stenger, S; Thole, J; Verreck, FA W; Williams, A; TBVAC2020 Consortium,;

2017

Frontiers in immunology, (2017).8 OCT 10.3389/fimmu.2017.01203.

Impact of the introduction of pneumococcal conjugate vaccination on pneumonia in The Gambia: population-based surveillance and case-control studies.

MACKENZIE, GA; Hill, PC; Sahito, SM; JEFFRIES, DJ; Hossain, I; BOTTOMLEY, C; Uchendu, U; Ameh, D; Ndiaye, M; Osuorah, CD; Adeyemi, O; Pathirana, J; Olatunji, Y; Abatan, B; Ahameefula, E; Muhammad, BS; Fombah, AE; Saha, D; Mackenzie, R; Plumb, I; Akano, A; Ebruke, B; Ideh, RC; Kuti, B; Githua, P; ... Corrah, T.

2017

The Lancet infectious diseases, (2017).17 9 10.1016/S1473-3099(17)30321-3.

Human papillomavirus (HPV) vaccine coverage achievements in low and middle-income countries 2007-2016.

GALLAGHER, KE; HOWARD, N; Kabakama, S; MOUNIER-JACK, S; BURCHETT, HE D; LaMontagne, DS; WATSON-JONES, D;

2017

Papillomavirus research (Amsterdam, Netherlands), (2017).4, 10.1016/j.pvr.2017.09.001.

Working together toward vaccines and biomarkers in the real world.

DOCKRELL, HM;

2017

Human vaccines & immunotherapeutics, (2017).13 7 10.1080/21645515.2017.1322443.

Kinetics of antibodies against pneumococcal proteins and their relationship to nasopharyngeal carriage in the first two months of life.

Mendy, AL; AGBLA, SC; ODUTOLA, AA; ANTONIO, M; GREENWOOD, BM; SUTHERLAND, JS; Ota, MO C;